Plimoth Trust Co. LLC Buys New Shares in Edwards Lifesciences Corporation $EW

Plimoth Trust Co. LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,093 shares of the medical research company’s stock, valued at approximately $242,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Boston Common Asset Management LLC boosted its position in shares of Edwards Lifesciences by 11.5% during the second quarter. Boston Common Asset Management LLC now owns 150,862 shares of the medical research company’s stock worth $11,799,000 after acquiring an additional 15,550 shares during the last quarter. Willner & Heller LLC purchased a new position in Edwards Lifesciences in the second quarter worth about $206,000. Ascent Group LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $250,000. Ameritas Advisory Services LLC bought a new position in Edwards Lifesciences during the second quarter valued at $88,000. Finally, River Street Advisors LLC purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $410,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.5%

Shares of EW opened at $77.03 on Monday. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $78.50 and its 200 day moving average price is $76.01. The firm has a market cap of $45.22 billion, a P/E ratio of 11.08, a price-to-earnings-growth ratio of 3.71 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Argus raised Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Finally, William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.